The Clinical Core (Core B) of the Johns Hopkins Alzheimer's Disease Research Center (ADRC) will be responsible for recruiting and following a diverse group of research subjects to support research projects associated with the ADRC. The Clinical Core accomplishes this overarching goal working closely with ADRC leadership and with the other Cores and Projects. The subjects in the Core include: (1) cognitively normal controls, (2) subjects meeting criteria for Mild Cognitive Impaimient (MCI), (3) patients with Alzheimer's disease (AD), and (4) patients with other related dementias. These cohorts include subjects recruited through the Clinic at Johns Hopkins Medical Institutions (known as the 'Clinic Cohort') as well as the subjects recruited through the Baltimore Longitudinal Study on Aging (BLSA) (known as the 'BLSA Cohort'). These subjects receive annual, standardized medical, neurologic, psychiatric and neuropsychological evaluations. Well-characterized, diverse subjects will be made available to research projects associated with the ADRC, working closely with the Education Core. The Clinical Core will work with the Neuropathology Core to collect, store and analyze plasma, serum, CSF, and DNA from normal controls, individuals with MCI, and cases of AD and related dementias, and to complete APOE genotyping on subjects. Core B will work closely with Core E and Core D to maintain a high autopsy rate (greater than 70%). Investigators in Core B will participate in collaborative research with other AD Centers, including multi-center therapeutic clinical trials related to AD. Core B will work with Core C to provide clinical data to the National Alzheimer's Coordinating Center (NACC) to further interdisciplinary research in AD.

Public Health Relevance

The Johns Hopkins Alzheimer's Disease Research Center (ADRC) will address many of the topics important to dementia research, with a particular focus on the understanding the earliest phases of Alzheimer's disease (AD). This approach is important if we are ultimately going to be able to diagnose and treat AD as early as possible. The ADRC fosters interactions among scientists who are pursuing this overarching theme.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-31
Application #
8662618
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
31
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Habes, Mohamad; Sotiras, Aristeidis; Erus, Guray et al. (2018) White matter lesions: Spatial heterogeneity, links to risk factors, cognition, genetics, and atrophy. Neurology 91:e964-e975
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Behrens, Stephanie; Rattinger, Gail B; Schwartz, Sarah et al. (2018) Use of FDA approved medications for Alzheimer's disease in mild dementia is associated with reduced informal costs of care. Int Psychogeriatr 30:1499-1507
Hanfelt, John J; Peng, Limin; Goldstein, Felicia C et al. (2018) Latent classes of mild cognitive impairment are associated with clinical outcomes and neuropathology: Analysis of data from the National Alzheimer's Coordinating Center. Neurobiol Dis 117:62-71
Lin, Ming; Gong, Pinghua; Yang, Tao et al. (2018) Big Data Analytical Approaches to the NACC Dataset: Aiding Preclinical Trial Enrichment. Alzheimer Dis Assoc Disord 32:18-27
Peng, Shin-Lei; Chen, Xi; Li, Yang et al. (2018) Age-related changes in cerebrovascular reactivity and their relationship to cognition: A four-year longitudinal study. Neuroimage 174:257-262
Bouhrara, Mustapha; Reiter, David A; Bergeron, Christopher M et al. (2018) Evidence of demyelination in mild cognitive impairment and dementia using a direct and specific magnetic resonance imaging measure of myelin content. Alzheimers Dement 14:998-1004
Xiong, Yulan; Neifert, Stewart; Karuppagounder, Senthilkumar S et al. (2018) Robust kinase- and age-dependent dopaminergic and norepinephrine neurodegeneration in LRRK2 G2019S transgenic mice. Proc Natl Acad Sci U S A 115:1635-1640
Nicolas, Aude (see original citation for additional authors) (2018) Genome-wide Analyses Identify KIF5A as a Novel ALS Gene. Neuron 97:1268-1283.e6
Wong, Dean F; Comley, Robert A; Kuwabara, Hiroto et al. (2018) Characterization of 3 Novel Tau Radiopharmaceuticals, 11C-RO-963, 11C-RO-643, and 18F-RO-948, in Healthy Controls and in Alzheimer Subjects. J Nucl Med 59:1869-1876

Showing the most recent 10 out of 830 publications